December 26, 2013
Kissei Pharmaceutical announced on December 24 that it has entered into a license agreement with Pfizer Inc. of the US for granting Pfizer exclusive worldwide rights to develop and commercialize Kissei’s proprietary gout and hyperuricemia treatment KUX-1151 excluding Japan. Under...read more